Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 54 #1
TickerABT [NYSE, S&P 500]
CompanyAbbott Laboratories
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap62.54BEPS (ttm)1.39
P/E29.92EPS this Y319.40%
Forward P/E16.91EPS next Y9.67%
PEG2.46EPS past 5Y-13.00%
P/S2.87EPS next 5Y12.18%
P/B2.65EPS Q/Q0.00%
Dividend2.12%Sales Q/Q1.90%
Insider Own0.10%Inst Own68.90%
Insider Trans7.74%Inst Trans-0.06%
Short Float0.75%EarningsOct 22/b
Analyst Recom2.30Target Price44.79
Avg Volume4.57M52W Range35.06 - 43.97
23-Oct-14 12:51AM[$$] Abbott Sales Rise 5.8%; Mylan Terms Revised at The Wall Street Journal
22-Oct-14 06:43PMBiogen, Thermo Reports Disappoint; Abbott Accelerates at Investor's Business Daily
22-Oct-14 06:22PMAbbott, Mylan silent on why changing tax-inversion terms Reuters
22-Oct-14 04:59PMAbbott Laboratories Conference Call Highlights Benzinga
22-Oct-14 04:49PMAbbott Laboratories (ABT) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
22-Oct-14 12:18PMMylan-Abbott Inversion Deal Is On With Some Changes at The Wall Street Journal
22-Oct-14 10:22AMToday's Unusual Social Activity Stock: Abbott Laboratories (ABT) at TheStreet
22-Oct-14 10:15AMAbbott Labs' (ABT) Earnings Up Y/Y in Q3, Guidance Updated Zacks
22-Oct-14 09:24AMAbbott, Mylan back generics deal, tweak terms after tax rule change Reuters
22-Oct-14 09:00AMAbbott Laboratories Earnings Call scheduled for 9:00 am ET today CCBN
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company's Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company's Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fussell Stephen RExecutive Vice PresidentSep 18Option Exercise22.7931,900726,872141,664Sep 19 05:10 PM
FREYMAN THOMAS CExecutive Vice PresidentJul 21Option Exercise24.0779,0001,901,828390,326Jul 22 05:03 PM
Landgraf John CExecutive Vice PresidentJun 03Option Exercise31.9118,203580,771113,334Jun 05 05:09 PM
ASHLEY RICHARD WExecutive Vice PresidentMar 03Sale39.002,09881,829333,072Mar 04 05:06 PM
Warmuth Michael JExecutive Vice PresidentMar 03Sale39.0116,484642,96615,851Mar 04 05:04 PM
TickerAMAG [NASD]
CompanyAMAG Pharmaceuticals, Inc.
CountryUSA
IndustryDiagnostic Substances
Market Cap680.32MEPS (ttm)-0.57
P/E-EPS this Y43.60%
Forward P/E6.28EPS next Y923.30%
PEG-EPS past 5Y36.40%
P/S7.64EPS next 5Y-
P/B3.52EPS Q/Q22.20%
Dividend-Sales Q/Q26.50%
Insider Own2.70%Inst Own95.60%
Insider Trans48.63%Inst Trans1.26%
Short Float21.71%EarningsOct 22/b
Analyst Recom1.00Target Price39.00
Avg Volume477.78K52W Range16.49 - 33.57
21-Oct-14 07:31AMAMAG PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
20-Oct-14 06:57AMShould You Buy AMAG Pharmaceuticals (AMAG) Ahead of Earnings? Zacks
02-Oct-14 08:48AMCan the Rally in AMAG Pharmaceuticals (AMAG) Shares Continue? Zacks
30-Sep-14 04:10PMAMAG Up on Roughly $1B deal with Lumara to Widen Portfolio Zacks
30-Sep-14 06:42AMAMAG Pharma upgraded by FBR Capital Briefing.com
29-Sep-14 02:33PMAmag Pharma enters women health business with $675 mln deal Reuters
29-Sep-14 11:22AMWhy AMAG Pharmaceuticals (AMAG) Stock Is Up Today at TheStreet
29-Sep-14 11:13AMAmag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B at TheStreet
29-Sep-14 09:17AMMorning Movers: Athlon Soars on Encana Buyout; DreamWorks Jumps on Softbank Chatter at Barrons.com
29-Sep-14 08:31AMLumara Health to sell assets to AMAG, Perrigo for $757 million at MarketWatch
AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron replacement therapeutic agent in China. The company was founded in 1981 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
White Christopher GChief Business OfficerFeb 26Sale21.584008,63224,000Feb 26 05:11 PM
White Christopher GChief Business OfficerFeb 25Sale21.714349,42224,400Feb 26 05:11 PM
White Christopher GChief Business OfficerJan 09Sale20.832,00041,65924,834Jan 09 07:13 PM
White Christopher GChief Business OfficerJan 08Sale23.912,00047,82026,834Jan 09 07:13 PM
White Christopher GChief Business OfficerJan 07Sale24.102,50060,25028,834Jan 07 04:54 PM
TickerANGI [NASD]
CompanyAngie's List, Inc.
CountryUSA
IndustryInternet Software & Services
Market Cap390.33MEPS (ttm)-0.56
P/E-EPS this Y38.00%
Forward P/E151.59EPS next Y113.80%
PEG-EPS past 5Y-9.00%
P/S1.37EPS next 5Y29.90%
P/B-EPS Q/Q-24.00%
Dividend-Sales Q/Q33.30%
Insider Own5.10%Inst Own79.60%
Insider Trans-2.23%Inst Trans-6.96%
Short Float23.53%EarningsOct 22/b
Analyst Recom2.60Target Price12.53
Avg Volume1.50M52W Range6.28 - 19.80
22-Oct-14 05:14PMANGIE'S LIST, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Creation of a Direct Financial O EDGAR Online
22-Oct-14 04:28PMAs earnings season heats up, stocks close on the lows Yahoo Finance Blogs
22-Oct-14 01:36PMAngie's List Gets A Bad Review, Stock Slides On Bigger Loss Than Wall Street Wanted at Forbes
22-Oct-14 01:02PMAngie's List adds fewer members; shares plunge Reuters
22-Oct-14 11:39AM[$$] Angie's List Sees Ad Growth, Renewal Rates Slow at The Wall Street Journal
22-Oct-14 10:09AMWhy Angies List (ANGI) Stock Is Falling Today at TheStreet
22-Oct-14 07:27AMAngie's List misses Street 3Q forecasts AP
22-Oct-14 07:07AMQ3 2014 Angie's List Inc Earnings Release - Before Market Open CCBN
22-Oct-14 07:06AM7:06 am Angie's List reports EPS in-line, revs in-line; guides Q4 revs in-line Briefing.com
22-Oct-14 07:04AMANGIE'S LIST, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
Angie's List, Inc. operates a consumer-driven solution for its members to research, hire, rate, and review local professionals for home, health care, and automotive service needs. It offers member services comprising member-generated ratings and reviews that provide reviews from members and non-members in approximately 720 categories; and service provider services for members looking for reputable providers of high cost of failure services. As of December 31, 2013, it had approximately 2.5 million paid memberships in 253 local markets in the United States. The company was formerly known as Brownstone Publishing, LLC and changed its name to Angie's List, Inc. in April 2010. Angie's List, Inc. was founded in 1995 and is headquartered in Indianapolis, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TRI Ventures, Inc.10% OwnerOct 15Buy8.182,53220,70411,626,652Oct 16 04:22 PM
Chuang John H.DirectorOct 15Buy8.182,53220,70411,626,652Oct 16 04:23 PM
Kapner Steven M.DirectorOct 15Buy8.182,53220,70411,626,652Oct 16 04:23 PM
TRI Ventures, Inc.10% OwnerSep 15Buy7.782,66320,72311,624,120Sep 16 04:17 PM
Chuang John H.DirectorSep 15Buy7.782,66320,72311,624,120Sep 16 04:19 PM
TickerAPH [NYSE, S&P 500]
CompanyAmphenol Corporation
CountryUSA
IndustryDiversified Electronics
Market Cap14.81BEPS (ttm)2.05
P/E22.99EPS this Y16.00%
Forward P/E19.31EPS next Y10.01%
PEG2.08EPS past 5Y10.90%
P/S2.99EPS next 5Y11.04%
P/B4.98EPS Q/Q14.90%
Dividend1.06%Sales Q/Q15.70%
Insider Own0.30%Inst Own97.80%
Insider Trans20.12%Inst Trans-0.02%
Short Float1.35%EarningsOct 22/b
Analyst Recom2.50Target Price52.27
Avg Volume1.38M52W Range39.37 - 52.97
22-Oct-14 04:45PMAmphenol (APH) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
22-Oct-14 01:00PMAmphenol Earnings Call scheduled for 1:00 pm ET today CCBN
22-Oct-14 12:20PMAmphenol Beats Q3 Earnings with Record Sales, Guidance Up Zacks
22-Oct-14 11:11AMTrade-Ideas: Amphenol (APH) Is Today's "Roof Leaker" Stock at TheStreet
22-Oct-14 11:02AMAMPHENOL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
22-Oct-14 08:15AMAmphenol tops Street 3Q forecasts AP
22-Oct-14 08:06AM8:06 am Amphenol beats by $0.01, beats on revs; guides Q4 EPS in-line, revs in-line Briefing.com
22-Oct-14 08:00AMThird Quarter 2014 Record Results Reported by Amphenol Corporation Business Wire
22-Oct-14 07:07AMQ3 2014 Amphenol Earnings Release - Before Market Open CCBN
20-Oct-14 05:00PMWill Amphenol (APH) Miss on Q3 Earnings Despite Strengths? Zacks
Amphenol Corporation designs, manufactures, and markets electrical, electronic, and fiber optic connectors; interconnect systems, antennas, sensors, and sensor-based products; and coaxial and specialty cables worldwide. The company's Interconnect Products and Assemblies segment produces connectors and connector systems, including fiber optic, harsh environment, high speed, and radio frequency interconnect products and antennas; power interconnect products, bus bars, and distribution systems; and other connectors. It also offers value-add products, such as backplane interconnect systems, cable assemblies and harnesses, and cable management products; and other products comprising antennas, printed circuit boards, hinges, installation accessories, molded parts, sensors and sensor-based products, switches, and touch panels and lenses. The company's Cable Products and Solutions segment provides coaxial, power, and specialty cables; cable assemblies; and components comprising combiner/splitter products, connector and connector systems, and fiber optic components. Amphenol Corporation serves original equipment manufacturers, electronic manufacturing companies, and original design manufacturers in the automotive, broadband communication, commercial aerospace, industrial, information technology and data communication, military, mobile device, and mobile network end markets. The company sells its products through its own sales force, independent representatives, and a network of electronics distributors. Amphenol Corporation was founded in 1932 and is headquartered in Wallingford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Raley Zachary WSVP GGM WW RF & MICRO PRODSep 08Option Exercise32.01110,0003,521,100110,000Sep 09 03:37 PM
Raley Zachary WSVP GGM WW RF & MICRO PRODSep 08Sale104.00110,00011,440,1650Sep 09 03:37 PM
Lampo Craig AVP & CONTROLLERAug 12Option Exercise34.556,000207,3006,000Aug 12 03:39 PM
Lampo Craig AVP & CONTROLLERAug 12Sale99.776,000598,6440Aug 12 03:39 PM
Carroccia FrankVP & GGM, GLBL INTERC SYS GRPJul 30Option Exercise48.3836,6001,770,63412,300Jul 31 07:52 AM
TickerBA [NYSE, DJIA, S&P500]
CompanyThe Boeing Company
CountryUSA
IndustryAerospace/Defense Products & Services
Market Cap87.52BEPS (ttm)6.64
P/E18.29EPS this Y16.80%
Forward P/E14.22EPS next Y3.33%
PEG1.71EPS past 5Y10.30%
P/S0.99EPS next 5Y10.68%
P/B6.30EPS Q/Q58.90%
Dividend2.40%Sales Q/Q1.10%
Insider Own0.08%Inst Own75.10%
Insider Trans-5.10%Inst Trans-0.06%
Short Float1.89%EarningsOct 22/b
Analyst Recom2.10Target Price153.18
Avg Volume4.31M52W Range116.32 - 142.10
23-Oct-14 03:41AMSaab Closes in on Gripen Deal in Brazil Opening Up Latin America at Bloomberg
23-Oct-14 12:51AM[$$] Boeing Posts Strong Results, Raises Outlook Again at The Wall Street Journal
23-Oct-14 12:18AMWhy Boeing's stock shrugged off robust Q3 results CNBC
22-Oct-14 07:01PMBoeing profit jumps 18% at Los Angeles Times
22-Oct-14 06:41PMBoeing Profit Tops But Faster Output Slashes Cash Flow Investor's Business Daily
22-Oct-14 05:46PMBoeings Earnings Jump, but Higher Costs for 787 Weigh on Its Shares at New York Times
22-Oct-14 05:27PMBoeing (BA) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
22-Oct-14 05:18PMToday's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
22-Oct-14 04:44PMBoeing Q3 profit jumps on airliner demand at USA TODAY
22-Oct-14 04:25PMStock Market Today: Markets Tumble Into Close on Oil Inventory, Canadian Shooting at TheStreet
The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital. The Commercial Airplanes segment develops, produces, and markets commercial jet aircraft for various passenger and cargo requirements, as well as provides related support services to the commercial airline industry. This segment also provides aviation services support, aircraft modifications, spares, training, maintenance documents, and technical advice to commercial and government customers. The Boeing Military Aircraft segment is involved in the research, development, production, and modification of manned and unmanned military aircraft and weapons systems for the global strike and vertical lift, mobility, surveillance, and engagement. The Network & Space Systems segment is engaged in the research, development, production, and modification of electronics and information solutions; strategic missile and defense systems; space and intelligence systems; and space exploration products. The Global Services and Support segment offers a range of products and services comprising integrated logistics, including supply chain management and engineering support; maintenance, modification, and upgrades for aircraft; and training systems and government services, such as pilot and maintenance training. The Boeing Capital segment facilitates, arranges, structures, and provides financing solutions, such as equipment under operating leases, finance leases, notes and other receivables, assets held for sale or re-lease, and investments for its commercial airplanes customers. The Boeing Company was founded in 1916 and is based in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hill Shephard WSVP, President, Boeing Int'lMay 08Option Exercise73.8665,8204,861,219128,445May 09 04:09 PM
Hill Shephard WSVP, President, Boeing Int'lMay 08Sale130.7765,8208,607,08462,625May 09 04:09 PM
Downey Thomas JSVP, CommunicationsMay 05Sale131.252,912382,20060,048May 07 04:17 PM
DUBERSTEIN KENNETH MDirectorMay 02Option Exercise43.122,400103,4838,560May 05 05:28 PM
DUBERSTEIN KENNETH MDirectorMay 02Sale130.002,400312,0006,160May 05 05:28 PM
TickerBABY [NASD]
CompanyNatus Medical Inc.
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap1.06BEPS (ttm)0.92
P/E35.65EPS this Y469.20%
Forward P/E23.21EPS next Y15.54%
PEG1.62EPS past 5Y2.60%
P/S3.05EPS next 5Y22.00%
P/B3.12EPS Q/Q84.60%
Dividend-Sales Q/Q4.90%
Insider Own2.70%Inst Own86.50%
Insider Trans-4.70%Inst Trans0.45%
Short Float4.82%EarningsOct 22/b
Analyst Recom2.00Target Price30.00
Avg Volume288.92K52W Range14.60 - 32.44
22-Oct-14Reiterated ROTH Capital Buy $33 → $36
22-Oct-14 11:00AMNatus Medical Inc Earnings Call scheduled for 11:00 am ET today CCBN
22-Oct-14 07:57AMNatus Medical tops Street 3Q forecasts AP
22-Oct-14 07:19AMNATUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
22-Oct-14 07:07AMQ3 2014 Natus Medical Inc Earnings Release - Before Market Open CCBN
22-Oct-14 07:04AM7:04 am Natus Medical beats by $0.02, beats on revs; guides Q4 EPS in-line, revs above consensus Briefing.com
22-Oct-14 07:00AMNatus Medical Announces Record Third Quarter and Year-to-Date 2014 Financial Results GlobeNewswire
21-Oct-14 09:51AMDon't Miss Today's Strong And Under The Radar Stock: Natus Medical (BABY) at TheStreet
16-Oct-14 05:33PMMarket Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
16-Oct-14 07:00AMNatus Medical Announces First of Kind Vista Ultrasound System GlobeNewswire
08-Oct-14 07:00AMNatus Medical to Hold 2014 Third Quarter Financial Results Conference Call on October 22nd GlobeNewswire
Natus Medical Incorporated provides newborn care and neurology healthcare products worldwide. It offers healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and incubators to control the newborn's environment; and software systems for managing and tracking disorders and diseases for public health laboratories. It provides ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners; and hearing screening supply products that are used with newborn hearing screening devices. The company also offers diagnostic hearing assessment product lines, which include the Navigator Pro system, the Scout sport portable diagnostic device, and the AuDX PRO; and diagnostic hearing supply products. In addition, it provides monitoring systems, balance and mobility products, newborn brain injury diagnostic products, thermoregulation products, and jaundice management products. Further, the company offers photometers, radiometers, patient warming lamps, neonatal heatshields, pediatric scales, blanket warming cabinets, exam lights, oxygen hoods, restraining boards, and newborn circumstraint; neonatal noise attenuators, phototherapy eye masks, and x-ray shields for reproductive organs; and newborn screening data management products. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOORE WILLIAM MDirectorSep 08Sale29.175,000145,850133,892Sep 10 08:42 PM
Noll Austin Francis IIIVP/GM NeurologyJul 30Option Exercise11.9223,500280,12076,500Jul 31 02:06 PM
Noll Austin Francis IIIVP/GM NeurologyJul 30Sale29.4223,500691,37053,000Jul 31 02:06 PM
LUDLUM KENDirectorMay 30Option Exercise20.092,50050,22582,200Jun 03 01:15 PM
LUDLUM KENDirectorMay 30Sale24.772,50061,92579,700Jun 03 01:15 PM
TickerBEAV [NASD]
CompanyB/E Aerospace Inc.
CountryUSA
IndustryAerospace/Defense Products & Services
Market Cap7.84BEPS (ttm)3.85
P/E19.34EPS this Y55.10%
Forward P/E14.06EPS next Y18.66%
PEG0.98EPS past 5Y39.90%
P/S2.01EPS next 5Y19.70%
P/B2.71EPS Q/Q16.90%
Dividend-Sales Q/Q28.10%
Insider Own0.10%Inst Own91.80%
Insider Trans-3.66%Inst Trans-0.67%
Short Float4.27%EarningsOct 22/b
Analyst Recom1.90Target Price101.21
Avg Volume1.45M52W Range69.18 - 101.13
22-Oct-14 04:43PMMarkets Reverse Early Morning Gains Following Canadian Shooting Benzinga
22-Oct-14 03:35PMB/E Aerospace (BEAV) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
22-Oct-14 09:01AMStock Futures Upshift On Data; Yahoo, Broadcom, Boeing Climb at Investor's Business Daily
22-Oct-14 08:00AMB/E Aerospace Inc Earnings Call scheduled for 8:00 am ET today CCBN
22-Oct-14 07:07AMQ3 2014 B/E Aerospace Inc Earnings Release - Before Market Open CCBN
22-Oct-14 06:04AMB/E AEROSPACE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
22-Oct-14 05:03AMB/E Aerospace tops 3Q net income expectations AP
22-Oct-14 03:25AM3:25 am BE Aerospace beats by $0.02, reports revs in-line; guides FY14 EPS in-line Briefing.com
22-Oct-14 02:00AMB/E Aerospace Reports Third Quarter 2014 Financial Results Business Wire
20-Oct-14 09:24AMWill This Price Target Decrease Hurt B/E Aerospace (BEAV) Stock Today? at TheStreet
B/E Aerospace, Inc. designs, manufactures, sells, and services cabin interior products for commercial aircraft and business jets in the United States and internationally. Its Commercial Aircraft segment offers first class, business class, tourist class, and regional aircraft seats, as well as spares; oxygen storage, distribution, and delivery systems for commercial and business jet aircraft; coffee makers/water boilers, ovens, and refrigeration equipment; and modular lavatory, wastewater, and galley systems. This segment also provides engineering, design, integration, installation, and certification services for commercial aircraft passenger cabin interiors; services to design, manage, integrate, test, and certify reconfigurations and modifications for commercial aircraft, as well as to manufacture engineering kits and interface components; and interior reconfiguration services. The company's Consumables Management segment offers inventory management and replenishment, special packaging and bar-coding, sophisticated parts kitting, quality assurance testing, and purchasing assistance services, as well as 3PL and 4PL supply chain programs; and distributes aerospace fasteners and other consumables. Its Business Jet segment provides jet seating and sofa products, including electric fully berthing lie-flat seats, direct and indirect lighting, air valves, and oxygen delivery systems, as well as sidewalls, bulkheads, credenzas, closets, galley structures, lavatories, wastewater systems, and table; and super first class cabin interior products for commercial wide-body aircraft. The company also offers thermal and power management solutions; and logistics related services, including oilfield rental equipment and services. It serves commercial and business jet aircraft operators, aircraft manufacturers, and their suppliers. The company was founded in 1987 and is headquartered in Wellington, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHOFIELD JONATHAN MDirectorSep 11Sale86.215,004431,38139,277Sep 15 05:14 PM
Exton WayneVice President & GMDec 19Sale84.823,000254,46029,864Dec 20 04:15 PM
Patch Ryan MVP,General Counsel & SecretaryDec 17Sale85.081,525129,74724,471Dec 17 05:49 PM
MCCAFFREY THOMAS PSr. VP & CFODec 17Sale85.503,283280,70139,771Dec 17 06:22 PM
Cromie SeanVice President & GMDec 17Sale85.501,436122,78023,047Dec 17 04:31 PM
TickerBIIB [NASD, S&P 500]
CompanyBiogen Idec Inc.
CountryUSA
IndustryBiotechnology
Market Cap72.98BEPS (ttm)9.00
P/E34.34EPS this Y35.60%
Forward P/E19.13EPS next Y23.33%
PEG1.64EPS past 5Y24.10%
P/S8.75EPS next 5Y20.90%
P/B7.65EPS Q/Q46.10%
Dividend-Sales Q/Q40.50%
Insider Own0.10%Inst Own92.00%
Insider Trans2.16%Inst Trans-0.28%
Short Float1.32%EarningsOct 22/b
Analyst Recom2.20Target Price376.76
Avg Volume1.29M52W Range230.25 - 358.89
22-Oct-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
22-Oct-14 06:43PMBiogen, Thermo Reports Disappoint; Abbott Accelerates at Investor's Business Daily
22-Oct-14 05:18PMToday's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
22-Oct-14 04:43PMMarkets Reverse Early Morning Gains Following Canadian Shooting Benzinga
22-Oct-14 04:28PMAs earnings season heats up, stocks close on the lows Yahoo Finance Blogs
22-Oct-14 04:24PMMajor Indexes End Win Streak; Super Micro Surges at Investor's Business Daily
22-Oct-14 03:06PMStocks Erase Modest Gains; Apple Flirts With Breakout at Investor's Business Daily
22-Oct-14 01:24PMBiogen Idec upgraded by Robert W. Baird Briefing.com
22-Oct-14 12:50PMDow Chemical rallies on strong earnings at Financial Times
22-Oct-14 12:39PMWhy Biogen Idec (BIIB) Stock Is Tanking Today at TheStreet
22-Oct-14 12:10PMBiogen's Q3 Earnings Top Estimates, View Raised Again Zacks
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn's disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company's products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
TickerBPOP [NASD]
CompanyPopular, Inc.
CountryUSA
IndustryForeign Regional Banks
Market Cap3.08BEPS (ttm)1.21
P/E24.61EPS this Y146.00%
Forward P/E9.00EPS next Y32.67%
PEG4.92EPS past 5Y17.40%
P/S1.79EPS next 5Y5.00%
P/B0.73EPS Q/Q-206.60%
Dividend-Sales Q/Q2.10%
Insider Own0.90%Inst Own88.40%
Insider Trans-34.84%Inst Trans9.56%
Short Float2.83%EarningsOct 22/b
Analyst Recom2.00Target Price37.71
Avg Volume921.00K52W Range24.71 - 34.95
22-Oct-14 09:39AMPOPULAR INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
22-Oct-14 08:06AM8:06 am Popular reports Q3 results; Net interest income declined 2.1% Briefing.com
22-Oct-14 08:00AMPopular, Inc. Announces Third Quarter Financial Results Business Wire
22-Oct-14 07:07AMQ3 2014 Popular Inc Earnings Release - Before Market Open CCBN
03-Oct-14 09:10AMPopular, Inc. Declares Dividends on Preferred Stock, Announces Distribution on Trust Preferred Securities Business Wire
29-Sep-14 09:20AMPOPULAR INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; EDGAR Online
29-Sep-14 07:55AMPopular Announces Appointment of Ignacio Alvarez as President and Chief Operating Officer and Javier D. Ferrer as Executive Vice President and General Counsel Business Wire
24-Sep-14 04:10PMPopular, Inc. to Report Third-Quarter Results and Hold Conference Call on Wednesday, October 22, 2014 Business Wire
16-Sep-14 02:54PMPOPULAR INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
15-Sep-14 08:00AMPopular Community Bank Completes the Sale of its Central Florida Regional Operations Business Wire
Popular, Inc., through its subsidiaries, provides a range of retail and commercial banking products and services primarily to institutional and retail customers in Puerto Rico and the Mainland United States. The company accepts various deposit products. It also offers commercial and industrial, as well as commercial real estate loans; construction loans; lease financings comprising automobile loans/leases; residential mortgage and construction loans; consumer loans, including personal loans, credit cards, home equity lines of credit, and other loans to individual borrowers. In addition, the company provides financial advisory, investment banking, investment and securities brokerage, and insurance and reinsurance agency services. As of December 31, 2013, it owned and occupied approximately 63 branch premises and other facilities in Puerto Rico; and 94 offices comprising 16 owned and 78 leased in New York, Illinois, New Jersey, California, and Florida. Popular, Inc. was founded in 1917 and is headquartered in Hato Rey, Puerto Rico.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NESTOR O. RIVERAEXECUTIVE VICE PRESIDENTAug 29Sale30.9814,085436,35325,103Sep 03 12:29 PM
GOEL DAVID E.DirectorMay 15Sale28.53250,0007,132,5000May 16 04:30 PM
GOEL DAVID E.DirectorMay 14Sale29.29216,1766,331,7954,216May 16 04:30 PM
CARRION RICHARD LChairman & CEOFeb 24Sale26.8693,6502,515,439204,472Feb 25 04:15 PM
GOEL DAVID E.DirectorJan 30Sale26.60300,0007,980,0008,906Jan 30 07:28 PM
TickerBSX [NYSE, S&P 500]
CompanyBoston Scientific Corporation
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap16.33BEPS (ttm)0.18
P/E68.44EPS this Y96.90%
Forward P/E13.73EPS next Y9.66%
PEG6.51EPS past 5Y41.90%
P/S2.26EPS next 5Y10.51%
P/B2.49EPS Q/Q-100.00%
Dividend-Sales Q/Q3.50%
Insider Own1.01%Inst Own90.90%
Insider Trans-0.30%Inst Trans0.00%
Short Float2.54%EarningsOct 22/b
Analyst Recom2.30Target Price14.48
Avg Volume11.68M52W Range11.10 - 14.08
23-Oct-14 12:01AMBoston Scientific Turnaround Complete, CEO Mahoney Says at Bloomberg
22-Oct-14 01:50PMBoston Scientific Earnings, Revenues in Line; View Up Zacks
22-Oct-14 11:50AMAfter Multiyear Turnaround, Is Boston Scientific Finally (and Really) Back? at 24/7 Wall St.
22-Oct-14 11:08AMBoston Scientific (BSX) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
22-Oct-14 10:38AMWhy Boston Scientific (BSX) Stock Is Up Today at TheStreet
22-Oct-14 10:36AMMorgan Stanley Reviews Boston Scientific Q3 Results Benzinga
22-Oct-14 09:03AM[$$] Boston Scientific Swings to Profit on Higher Sales at The Wall Street Journal
22-Oct-14 08:18AMBoston Scientific 3rd-qtr profit up on heart device sales Reuters
22-Oct-14 08:00AMBoston Scientific Corp Earnings Call scheduled for 8:00 am ET today CCBN
22-Oct-14 07:53AMAbbotts Profit Rises as Nutrition Products Grow at Bloomberg
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorOct 08Sale12.0610,000120,600267,855Oct 09 04:06 PM
MARIO ERNESTDirectorSep 02Sale12.6010,000125,992277,855Sep 03 04:11 PM
Phalen Michael P.EVP & President, MedSurgAug 15Option Exercise7.6311,47187,473138,957Aug 15 04:20 PM
Phalen Michael P.EVP & President, MedSurgAug 15Sale12.5811,471144,305127,486Aug 15 04:20 PM
MARIO ERNESTDirectorAug 01Sale12.5810,000125,817287,855Aug 05 04:13 PM
1 2 3 4 5 6 next